Traphagen Investment Advisors 13F: New $221K Stake in CAH
An SEC filing shows Traphagen Investment Advisors added a brand-new stake in Cardinal Health, Inc. during the recent period.
Reviewed by automated data checks against the source filing. How we make and check alerts
Traphagen Investment Advisors opened a new position of 992 shares in Cardinal Health, Inc. ($CAH), according to a 13F filing with the SEC dated October 14, 2026. It reported 992 shares worth $220,729 at the end of the quarter.
Since the filing, $CAH is up 2.5% to date (from the $247.74 close on Oct 14, 2026).
Find the original: Traphagen Investment Advisors 13F filings on SEC EDGAR
CAH
Cardinal Health, Inc.
Key Points
- Traphagen Investment Advisors bought a new stake of 992 shares in Cardinal Health, Inc., valued at about $220,729, according to a Form 13F filing on October 14, 2026.
- Other large institutional investors adjusted their holdings, with Wellington Management Group, LLP boosting its position by 10,584,180 shares to end with 14,860,271 shares worth about $3,775,400,413.
- Cardinal Health trades recently around $252.44, sitting above its 50-day moving average of $234.07 as it heads toward its next earnings report on November 5, 2026.
Get $CAH trade alerts by text
We text you when insiders, Congress or big funds trade $CAH. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Cardinal Health, Inc. alert may contain errors. Disclosures
Traphagen Investment Advisors opened a brand-new position in Cardinal Health, Inc. CAH, picking up 992 shares worth roughly $220,729. The move came to light in a Form 13F filing with the Securities and Exchange Commission on October 14, 2026. Keep in mind that 13F filings are backward-looking, reflecting holdings as of the end of the reporting quarter, so this disclosure may not reflect the fund's current holdings today. Because this was a fresh purchase, the fund had no prior shares in the company.
Inside Traphagen Investment Advisors's Cardinal Health Trade
The newly established stake gives the firm a small foothold in the healthcare distributor. The reported value of the shares stands at $220,729 based on the details provided in the filing. Because 13F reports look back at prior quarters, investors often review these filings to see which companies are landing on smaller investment radar screens.
Other Institutional Activity in Cardinal Health
Other large funds made substantial adjustments to their Cardinal Health shares during the period. Wellington Management Group, LLP grew its holdings by 10,584,180 shares, ending with 14,860,271 shares worth about $3,775,400,413. Blackrock Inc. reduced its holdings by 2,003,110 shares, ending with 26,490,633 shares worth about $6,730,210,155. Vanguard Capital Management LLC grew its holdings by 3,058 shares, ending with 15,292,186 shares worth about $3,885,132,737. Vanguard Portfolio Management LLC reduced its holdings by 13,732 shares, ending with 13,717,894 shares worth about $3,485,168,116. State Street Corporation reduced its holdings by 107,464 shares, ending with 11,967,121 shares worth about $3,040,366,732.
Cardinal Health, Inc. Stock Down 0.5%
Cardinal Health shares recently traded around $252.44. The stock trades above its 50-day moving average of $234.07 and its 200-day moving average of $219.64. The shares sit below their 52-week high of $258.30.
Recent Earnings
Cardinal Health posted trailing-twelve-month revenue of $254,247,993,344 alongside trailing-twelve-month earnings per share of $7.23. The company's net margin stands at 0.7% with a year-over-year revenue growth rate of 5.8%. The next earnings report is scheduled for November 5, 2026.
Earnings drift grade
Outlook vs expectations on the last report — not price action.
-
Forward outlook
2 target raises vs 2 cuts.
-
EPS & revenue
EPS beat estimates by 12.6%. Revenue missed estimates by 2.2%.
-
Profit surprise
EBITDA missed by 27 percent. Operating income missed by 46 percent.
-
Pre-earnings setup
Bar was high, analysts already very bullish.
-
Analyst signal
2 target raises, 2 target cuts.
-
Earnings quality
Positive free cash flow.
Earnings Call Summary
Cardinal Health reported first quarter revenue of $60.9 billion, up 22 percent year over year, with earnings per share of $3.17 beating consensus of $2.80. The company saw broad strength across all five business segments, particularly in pharmaceutical specialty solutions where profit grew 26 percent and specialty drug sales benefited from GLP-1 demand growth. The strong quarter reflected execution on strategy, successful integration of acquisitions, and robust underlying pharmaceutical utilization trends across the market.
Guidance Cardinal Health raised its full year earnings guidance to between $9.65 and $9.85 per share, up 35 cents from prior guidance. The company expects Pharma profit to grow 16 to 19 percent for the year, driven by strong drug demand and the Solaris Health acquisition closing soon. Free cash flow is now guided to $3 billion to $3.5 billion for the full year, up from prior range.
Clearly negative report. The company missed important expectations and likely triggers downward revisions.
Dividend
Cardinal Health pays an annual dividend rate of $2.06 per share, giving it a dividend yield of 0.81%. The payout ratio sits at 28.3%.
Insider Buying and Selling at Cardinal Health, Inc.
Company insiders executed several transactions over the summer. Stephen M Officer sold 35,000 shares on August 18, 2026, for a total value of $8,274,117. Michelle D Greene, Chief Technology Officer, sold 11,650 shares on August 18, 2026, for $2,746,187. Mary C Officer sold 2,302 shares on August 19, 2026, for $546,473. Jason M Hollar, Chief Executive Officer, sold 124,529 shares on August 19, 2026, for $29,375,516.
Analysts Set New Price Targets
Wall Street firms updated their views on the stock over the summer. On August 12, 2026, Citigroup maintained a Buy rating and raised its price target to $280.00 from $265.00. On August 13, 2026, TD Cowen maintained a Buy rating and raised its target to $280.00 from $275.00. On August 13, 2026, JP Morgan maintained a Neutral rating and lifted its target to $260.00 from $215.00. On August 13, 2026, Barclays maintained an Overweight rating and raised its target to $275.00 from $258.00. On August 19, 2026, RBC Capital initiated coverage with an Outperform rating and a $276.00 price target. Overall, analysts hold a consensus Buy rating on the stock with a mean price target of $270.47 based on 15 analyst opinions.
About Cardinal Health
Cardinal Health operates as a healthcare services and products company, supplying pharmaceuticals, medical products, and customized distribution solutions to hospitals, pharmacies, clinical laboratories, and healthcare systems around the world. Institutional interest in the company reflects its steady role in the medical supply chain.
Bottom Line
Investors tracking Traphagen Investment Advisors will look to future SEC filings to see whether the firm expands or exits its new holding. The company's upcoming earnings release on November 5, 2026, will offer fresh operational details. Remember that 13F reports reflect past quarterly positions rather than real-time trading activity.
Related Filing Alerts
Source: Traphagen Investment Advisors's 13F filing on $CAH (Oct 14, 2026). 13F filings show holdings as of the end of the reporting quarter and may not reflect the fund's current position. Find the original filing: Traphagen Investment Advisors 13F filings on SEC EDGAR. Written by software, not financial advice. How we make alerts